UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018248
Receipt number R000021119
Scientific Title Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia
Date of disclosure of the study information 2015/07/09
Last modified on 2022/03/07 08:29:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia

Acronym

Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia

Scientific Title

Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia

Scientific Title:Acronym

Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia

Region

Japan


Condition

Condition

advanced squamous cell lung cancer with idiopathic interstitial pneumonia

Classification by specialty

Pneumology Hematology and clinical oncology Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the safety and the efficacy of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

response rate

Key secondary outcomes

OS: overall survival
PFS: progression free survival
TTF: Time to treatment failure
toxicity


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Carboplatin AUC = 5 , day1
Paclitaxel 70mg/m2, day1,8,15
4-6 cycle

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Squamous cell lung cancer
2) Age over twenty
3) Idiopathic interstitial pneumonia
4) Measurable lesion
5) ECOG performance status 0 or 1
6) Adequate organ function
WBC>=3000/mm3 and neutrophil count >=2000/mm3
Hgb>=10.0 g/dL, Plt>=100,000/mm3, T-bil=<1.5mg/dL, AST=<100 IU/L, ALT=<100 IU/L, CRN=<1.5mg/dL
7) PaO2>=60.0 torr or SpO2>=92.0 %( room air)
8) No symptoms from brain metastasis
9) Life expectancy > 3 months
10) Written informed consent

Key exclusion criteria

1) Secondly interstitial pneumonia.
2) History of acute exacerbation of interstitial pneumonia within 3 months.
3) Subacute progression of interstitial pneumonia within 3 months.
4) Using prednisolone or immune-suppressive agent.
5) Need to home oxygen therapy.
6) Past history of severe drug allergy.
7) Active infectious disease.
8) Severe complications
9) Symptomatic brain metastasis.
10) Uncontrollable effusion.
11) Active combined malignancy
12) Any ineligible case judged by physician.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nobuyuki Katakami

Organization

Institute of Biomedical Research and Innovation Hospital

Division name

Division of Integrated Oncology

Zip code


Address

2-2, Minatojima Minamimachi Chuo-ku, Kobe 650-0047, Japan

TEL

078-304-5200

Email

katakami@fbri.org


Public contact

Name of contact person

1st name
Middle name
Last name Hidekazu Suzuki

Organization

Osaka Preferctural Medical Center for Respiratory and Allegic Diseases

Division name

Thoracic Oncology

Zip code


Address

3-7-1 Habikino Habikino-shi Osaka 583-8588 Japan

TEL

072-957-2121

Homepage URL


Email

suzukih@opho.jp


Sponsor or person

Institute

IP lung cancer study group

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 07 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2012 Year 11 Month 21 Day

Date of IRB

2012 Year 10 Month 13 Day

Anticipated trial start date

2012 Year 12 Month 01 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 07 Month 08 Day

Last modified on

2022 Year 03 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021119


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name